2. Academic Validation
  3. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors

Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors

  • J Med Chem. 2007 Mar 22;50(6):1146-57. doi: 10.1021/jm061319i.
David D Davey 1,  Marc Adler,  Damian Arnaiz,  Keith Eagen,  Shawn Erickson,  William Guilford,  Margaret Kenrick,  Michael M Morrissey,  Mike Ohlmeyer,  Gonghua Pan,  Vidyadhar M Paradkar,  John Parkinson,  Mark Polokoff,  Kurt Saionz,  Cecile Santos,  Babu Subramanyam,  Ron Vergona,  Robert G Wei,  Marc Whitlow,  Bin Ye,  Zuchun Spring Zhao,  James J Devlin,  Gary Phillips
Affiliations

Affiliation

  • 1 Berlex Biosciences, 2600 Hilltop Drive, P.O. Box 4099, Richmond, California 94804-0099, USA.
PMID: 17315988 DOI: 10.1021/jm061319i
Abstract

By the screening of a combinatorial library for inhibitors of nitric oxide (NO) formation by the inducible isoform of nitric oxide synthase (iNOS) using a whole-cell assay, 2-(imidazol-1-yl)pyrimidines were identified. Compounds were found to inhibit the dimerization of iNOS monomers, thus preventing the formation of the dimeric, active form of the enzyme. Optimization led to the selection of the potent, selective, and orally available iNOS dimerization inhibitor, 21b, which significantly ameliorated adjuvant-induced arthritis in a rat model. Analysis of the crystal structure of the 21b--iNOS monomer complex provided a rationalization for both the SAR and the mechanism by which 21b blocks the formation of the protein--protein interaction present in the dimeric form of iNOS.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z